Arca
Skip to content
Tools
Tools

Atopic dermatitis

Drug research and approvals for atopic dermatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 186 studies of atopic dermatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 206 drug trials for it since 2013, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 186
  • Trials authorized in Canada: 206
  • FDA orphan approvals: 0
  • EU medicines: 7

Recruiting now

Newest posted first, of 186 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 17

Phase 3 12 of 22

Phase 2 12 of 69

Phase 1 or earlier 12 of 23

How its trials ended

1,201 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 299 whose ending is known, 51% met their primary endpoint, 4% missed it and 44% stopped early.

  • Completed, result not reported56247%
  • Ongoing24721%
  • Met its primary endpoint15313%
  • Status unknown938%
  • Stopped: other or unclear615%
  • Stopped: lack of efficacy242%
  • Stopped: enrollment or feasibility222%
  • Stopped: sponsor or business decision202%
  • Missed its primary endpoint131%
  • Stopped: funding6<1%

Trials authorized in Canada

The 10 newest of 206; search them all in Canada trials
Sep 16, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsPending
Sep 10, 2026A randomized, double-blind, parallel group, placebo-controlled phase 3 combination therapy study to investigate the efficacy & safety oftilrekimig in adult &…Tilrekimig (PF-07275315)PfizerOngoing
Sep 2, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing
Sep 2, 2026A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358)Nektar TherapeuticsOngoing
Aug 12, 2026A phase 2, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of multiple subcutaneous…TRIV-573Triveni Bio, Inc.Pending
Jun 18, 2026A phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in…Soquelitinib (CPI-818)Corvus PharmaceuticalsOngoing
Jun 8, 2026A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of ENV-294 in adult…ENV-294Enveda TherapeuticsPending
Jun 4, 2026A long-term extension study to evaluate the safety and efficacy of subcutaneous IMG-007 in participants of a previous IMG-007 moderate-to-severe atopic…IMG-007Inmagene LLCOngoing
Apr 9, 2026A phase 2b, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of camoteskimab in adults with…Camoteskimab (APL-9109)Apollo Therapeutics, LimitedOngoing
Dec 19, 2025A phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-95597528 for the treatment…JNJ-95597528Johnson & JohnsonOngoing

Medicines authorised in the EU

Newest first
Feb 12, 2025NemluvioNemolizumabGalderma InternationalEMA ↗
Nov 16, 2023EbglyssLebrikizumabAlmirall, S.A.EMA ↗
Apr 19, 2023OpzeluraRuxolitinibIncyte Biosciences Distribution B.V.EMA ↗
Dec 9, 2021CibinqoAbrocitinibPfizer Europe MA EEIGEMA ↗
Jun 17, 2021AdtralzaTralokinumabLEO Pharma A/SEMA ↗
Sep 26, 2017DupixentDupilumabSanofi Winthrop IndustrieEMA ↗
Feb 27, 2002ProtopicTacrolimusLEO Pharma A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.